Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV)

Human Vaccines

Volumn 6, Issue 7, 2010, Pages 554-561

  Knuf, Markus ^a   Vetter, Volker ^b,c,d   Celzo, Froilan ^b,c,d,e   Ramakrishnan, Gunasekaran ^b,c,d   Van Der Meeren, Olivier ^b,c,d   Jacquet, Jeanne M ^b,c,d  

^a Zentrum für Kinder und Jugendmedizin Universitätsmedizin   (Germany)

^b GLAXOSMITHKLINE   (Germany)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d GlaxoSmithKline Pharmaceuticals Ltd   (India)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Booster; Diphtheria; Pertussis; Poliomyelitis; Tetanus; Vaccination

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEMAGGLUTININ; MERIEUX; PERTACTIN; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; DIPHTHERIA TOXOID; DTPP VACCINE; PERTUSSIS VACCINE; TETANUS TOXOID; VIRUS ANTIBODY;

ADOLESCENT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL TRIAL; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; MULTICENTER STUDY; OPEN STUDY; PERTUSSIS; PHASE 4 CLINICAL TRIAL; SCHOOL CHILD; VACCINATION; VACCINATION REACTION; IMMUNIZATION; IMMUNOLOGY; METHODOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DIPHTHERIA TOXOID; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HUMANS; IMMUNIZATION, SECONDARY; PERTUSSIS VACCINE; POLIOVIRUS VACCINE, INACTIVATED; TETANUS TOXOID; VACCINATION; WHOOPING COUGH;

EID: 77957002518     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.7.11760     Document Type: Article

References (34)

1. Hellenbrand W, Beier D, Jensen E, Littmann M, Meyer C, Oppermann H, et al. The epidemiology of pertussis in Germany: past and present. BMC Infect Dis 2009; 9:22.
2. Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE; EUVAC-NET Group. Resurgence of pertussis in Europe. Pediatr Infect Dis J 2005; 24:761-5.
3. Güris D, Strebel PM, Bardenheier B, Brennan M, Tachdjian R, Finch E, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999; 28:1230-7.
4. Lee GM, Lett S, Schauer S, LeBaron C, Murphy TV, Rusinak D, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis 2004; 39:1572-80. (Pubitemid 39578527)
5. Lee GM, Riffelmann M, Wirsing von Konig CH. Cost-effectiveness of adult pertussis vaccination in Germany. Vaccine 2008; 26:3673-9.
6. O'Brien JA, Caro JJ. Hospitalization for pertussis: profiles and case costs by age. BMC Infect Dis 2005; 5:57.
7. Greenberg DP, von König CH, Heininger U. Health burden of pertussis in infants and children. Pediatr Infect Dis J 2005; 24:39-43.
8. McIntyre P, Wood N. Pertussis in early infancy: disease burden and preventive strategies. Curr Opin Infect Dis 2009; 22:215-23.
9. Edwards KM. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J 2005; 24:104-8.
10. Bisgard KM, Pascual FB, Ehresmann KR, Miller CA, Cianfrini C, Jennings CE, et al. Infant pertussis: who was the source? Pediatr Infect Dis J 2004; 23:985-9.
11. Wendelboe AM, Njamkepo E, Bourillon A, Floret DD, Gaudelus J, Gerber M, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007; 26:293-9.
12. Grimprel E, von Sonnenburg F, Sänger R, Abitbol V, Wolter JM, Schuerman LM. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine 2005; 23:3657-67. (Pubitemid 40692411)
13. Vergara R, Tregnaghi M, Ussher J, Navarro S, Rüttimann R, Potin M, et al. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr 2005; 164:377-82. (Pubitemid 40869012)
14. Sänger R, Behre U, Krause KH, Loch HP, Soemantri P, Herrmann D, et al. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine. Eur J Pediatr 2007; 166:1229-36. (Pubitemid 350029473)
15. Lin TY, Wang YH, Huang YC, Chiu CH, Lin PY, Tang H, et al. Booster vaccination at 6-8 years of age with a reduced antigen content dTpa-IPV vaccine is immunogenic and safe after priming with whole-cell pertussis vaccine. Hum Vaccin 2008; 4:50-3. (Pubitemid 351785261)
16. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005; 24:58-61.
17. th Annual Meeting of the European Society for Paediatric Infectious Diseases, ESPID 2009, Brussels, Belgium 2009.
18. th Annual Meeting of the Infectious Diseases Society of America (IDSA), Philadelphia, Pennsylvania USA 2009.
19. Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, Englund JA, Meade BD, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000; 105:12.
20. Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Ped Infect Dis 2003; 14:196-8.
21. Pichichero M, Deloria M, Rennels M, Anderson E, Edwards K, Decker M, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given a fourth dose in 15- to 20-month-old children. Pediatrics 1997; 100:772-8.
22. Skowronski DM, Remple VP, Macnabb J, Pielak K, Patrick DM, Halperin SA, et al. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity and anticipated impact. Pediatrics 2003; 112:453.
23. Zepp F, Knuf M, Habermehl P, Mannhardt-Laakmann W, Howe B, Friedland LR. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. J Pediatr 2006; 149:603-10.
24. Zepp F, Habermehl P, Knuf M, Mannhardt-Laakman W, Howe B, Friedland LR. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. Vaccine 2007; 25:5248-52. (Pubitemid 46977539)
25. Hellwig SM, Rodriguez ME, Berbers GA, van de Winkel JG, Mooi FR. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis 2003; 188:738-42.
26. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16:1901-6. (Pubitemid 28473933)
27. Granström M, Granström G. Serological correlates in whooping cough. Vaccine 1993; 11:445-8.
28. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16:1907-16. (Pubitemid 28473934)
29. Guiso N, Njamkepo E, Vié le Sage F, Zepp F, Meyer CU, Abitbol V, et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 2007; 25:1390-7. (Pubitemid 46091822)
30. Meyer CU, Zepp F, Decker M, Lee M, Chang SJ, Ward J, et al. Cellular immunity in adolescents and adults following acellular pertussis vaccine administration. Clin Vaccine Immunol 2007; 14:288-92.
31. Cassone A, Ausiello CM, Urbani F, Lande R, Giuliano M, La Sala A, et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group. Arch Pediatr Adolesc Med 1997; 151:283-9.
32. Edelman K, He Q, Mäkinen J, Sahlberg A, Haanperä M, Schuerman L, et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 2007; 44:1271-7.
33. Giuliano M, Mastrantonio P, Giammanco A, Piscitelli A, Salmaso S, Wassilak SG. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J Pediatr 1998; 132:983-8.
34. World Health Organisation standard procedure for determining immunity to poliovirus using the microneutralization test (WHO/EPI/Gen 93.9).